Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) and CCA Industries (OTCMKTS:CAWW – Get Free Report) are both small-cap consumer staples companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability.
Earnings and Valuation
This table compares Dermata Therapeutics and CCA Industries”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dermata Therapeutics | N/A | N/A | -$7.56 million | ($4.39) | -0.32 |
| CCA Industries | $5.92 million | 0.50 | -$770,000.00 | ($0.01) | -45.00 |
Institutional and Insider Ownership
8.7% of Dermata Therapeutics shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by company insiders. Comparatively, 30.1% of CCA Industries shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations for Dermata Therapeutics and CCA Industries, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dermata Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| CCA Industries | 0 | 0 | 0 | 0 | 0.00 |
Profitability
This table compares Dermata Therapeutics and CCA Industries’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dermata Therapeutics | N/A | -166.66% | -130.13% |
| CCA Industries | -1.11% | -39.05% | -24.30% |
Volatility & Risk
Dermata Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, CCA Industries has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.
Summary
CCA Industries beats Dermata Therapeutics on 6 of the 11 factors compared between the two stocks.
About Dermata Therapeutics
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
About CCA Industries
CCA Industries, Inc. manufactures and distributes health and beauty aid products in the United States and internationally. It offers oral health-care products under the Plus+White brand; skin-care products under the Sudden Change and Porcelana brand names; nail treatments under the brand name of Nutra Nail; medicated topical and shave gels under the Bikini Zone brand; depilatories under the Hair Off brand and; perfumes under the brand name of Sunset Cafe. The company markets its products to drug, food, and mass-merchandise retail chains; warehouse clubs; and wholesale beauty-aids through independent sales representatives and distributors, as well as through Internet. CCA Industries, Inc. was incorporated in 1983 and is based in Lyndhurst, New Jersey.
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
